Developing c-MYC transcription inhibitors
that
target the G-quadruplex has generated significant interest; however,
few compounds have demonstrated specificity for c-MYC G-quadruplex and cancer cells. In this study, we designed and synthesized
a series of benzoazole derivatives as potential G-quadruplex ligand-based c-MYC transcription inhibitors. Surprisingly, benzoselenazole
derivatives, which are rarely reported as G-quadruplex ligands, demonstrated
greater c-MYC G-quadruplex selectivity and cancer
cell specificity compared to their benzothiazole and benzoxazole analogues.
The most promising compound, benzoselenazole m-Se3, selectively
inhibited c-MYC transcription by specifically stabilizing
the c-MYC G-quadruplex. This led to selective inhibition
of hepatoma cell growth and proliferation by affecting the MYC target
gene network, as well as effective tumor growth inhibition in hepatoma
xenografts. Collectively, our study demonstrates that m-Se3 holds significant promise as a potent and selective inhibitor of c-MYC transcription for cancer treatment. Furthermore, our
findings inspire the development of novel selenium-containing heterocyclic
compounds as c-MYC G-quadruplex-specific ligands
and transcription inhibitors.